Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Allos up on RSR13 NDA plans

ALTH was up $1.42 (61%) to $3.73 on 6.7 million shares on Thursday on news that it

Read the full 176 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE